Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors (Q35039274)

5 August 2017

1 reference

title

Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors (English)

1 reference

5 August 2017

1 reference

Francesca Pacifici

6

0 references

Maria Laura De Marchis

Maria Laura De Marchis

7

0 references

Mario Roselli

Mario Roselli

17

0 references

Davide Lauro

Davide Lauro

22

0 references

Patrizia Ferroni

Patrizia Ferroni

11

0 references

Pasquale Abete

Pasquale Abete

14

0 references

Raffaele Palmirotta

Raffaele Palmirotta

2

0 references

Antonello Pileggi

Antonello Pileggi

16

0 references

Camillo Ricordi

Camillo Ricordi

18

0 references

Ashish K Rehni

Ashish K Rehni

3

0 references

Tatjana Rundek

21

Tatjana Rundek

1 reference

5 August 2017

20

Fiorella Guadagni

1 reference

5 August 2017

David Della-Morte

1

1 reference

5 August 2017

Donatella Pastore

4

1 reference

5 August 2017

Barbara Capuani

5

1 reference

5 August 2017

Kunjan R Dave

8

1 reference

5 August 2017

Alfonso Bellia

9

1 reference

5 August 2017

Giuseppe Fogliame

10

1 reference

5 August 2017

Giulia Donadel

12

1 reference

5 August 2017

Francesco Cacciatore

13

1 reference

5 August 2017

Chuanhui Dong

15

1 reference

5 August 2017

Paolo Sbraccia

19

1 reference

5 August 2017

1 December 2014

1 reference

5 August 2017

1 reference

5 August 2017

15

1 reference

5 August 2017

2063-2082

1 reference

5 August 2017

16

1 reference

Current clinical evidence on pioglitazone pharmacogenomics.

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pharmacology of signaling pathways: in type 2 diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

LOX-1, OxLDL, and atherosclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Outcomes and lessons from the PROactive study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

8 July 2018

Thiazolidinedione safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Assessment of cardiac safety for PPARγ agonists in rodent models of heart failure: a translational medicine perspective

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

PPARγ agonist beyond glucose lowering effect.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pharmacogenetics of Anti-Diabetes Drugs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Effects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pharmacogenetics of thiazolidinedione therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Rosiglitazone for type 2 diabetes mellitus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes as a risk factor for alcoholic mild liver dysfunction

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pharmacokinetic interactions with thiazolidinediones

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pioglitazone for type 2 diabetes mellitus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

8 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

8 July 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome.

9 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Sequence variation in PPARG may underlie differential response to troglitazone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

The effect of PPARgamma ligands on the adipose tissue in insulin resistance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

PPARs: therapeutic targets for metabolic disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Vascular protective effects of cytochrome p450 epoxygenase-derived eicosanoids

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Adipose tissue as an endocrine organ: impact on insulin resistance.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Metabolic and additional vascular effects of thiazolidinediones.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Thiazolidinedione hepatotoxicity: a class effect?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

The mechanisms of action of PPARs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Pharmacokinetics and clinical efficacy of pioglitazone.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Peroxisome proliferator-activated receptor gamma and metabolic disease.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

The hormone resistin links obesity to diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor gamma in macrophages via an interaction with NRF2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

PPARgamma, the ultimate thrifty gene

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus

8 July 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pharmacogenomics of metabolic effects of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Effects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Effect of the Pro12Ala polymorphism of the PPAR gamma 2 gene on response to pioglitazone treatment in menopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Regulation of fasted blood glucose by resistin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Abnormal glucose homeostasis due to chronic hyperresistinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Genetic risk factors and the anti-atherosclerotic effect of pioglitazone on carotid atherosclerosis of subjects with type 2 diabetes--a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.14.162

Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Polymorphism of the leptin gene promoter in pedigrees of type 2 diabetes mellitus in Chongqing, China

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4314213

Hepatic dysfunction associated with troglitazone

25 October 2018

1 reference

12 December 2020

Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism

1 reference

12 December 2020

Pioglitazone decreased CD40/CD40L expression on human umbilical vein endothelial cells induced by oxidized low-density lipoprotein

1 reference

12 December 2020

Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes

1 reference

12 December 2020

Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

1 reference

12 December 2020

Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the li

1 reference

12 December 2020

Identifiers

DOI

10.2217/PGS.14.162

1 reference

5 August 2017

1 reference

5 August 2017

1 reference